CEBPA and intrahepatic cholangiocarcinoma: Furthermore, in line with the ICC 2022 classification, in-frame mutations affecting the bZIP region of CEBPA are now categorized as the favorable-risk group (Table 4) [13], replacing biallelic CEBPA mutations [12,13].